ArGEN-X pulls in €16M to push cancer, autoimmune programs to clinical POC

Nick Paul Taylor

Federated Investors has bought an 8.6% stake in arGEN-X. The deal sees arGEN-X sell shares worth €16 million ($ 17.5 million) to the major U.S. asset manager, giving it additional financial firepower at a time when it is closing in on proof-of-concept trials for a clutch of key drugs.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS